Clinico-hematological profile in biphenotypic acute leukemia

Indian Journal of Cancer

Volumn 46, Issue 2, 2009, Pages 160-168

  Gujral, S ^a   Polampalli, S ^a   Badrinath, Y ^a   Kumar, A ^a   Subramanian, P G ^a   Raje, G ^a   Amare, P ^a   Arora, B ^a   Banavali, S D ^a   Nair, C N ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Biphenotypic leukemia; Cytogenetics; Immunophenotyping

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; HLA DR ANTIGEN; IMATINIB;

ACUTE BIPHENOTYPIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CELL POPULATION; CHILD; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; CYTOCHEMISTRY; CYTOPLASM; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MORPHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SCORING SYSTEM; T LYMPHOCYTE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEMATOLOGIC TESTS; HUMANS; IMMUNOPHENOTYPING; INCIDENCE; LEUKEMIA, BIPHENOTYPIC, ACUTE; MALE; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 64749111976     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.49156     Document Type: Article

References (45)

1. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classifcation of acute leu-kemias European Group for the International Characterisation of Leukemias (EGIL). Leukemia 1995;10:1783-6.
2. Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, et al. Defnition of acute biphenotypic leukemia. Haematologica 1997;82:64-6.
3. Gale RP. Hybrid acute leukemia. Br J Haematol 1987;65:261-4.
4. World Health Organization Classifcation of Tumors, Pathology and Genetics, Tumors of Hematopoietic and Lymphoid Tissues. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. 2001. p. 75-118.
5. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Met 2000;243:59-75.
6. Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven JG, et al. Outcome of biphenotypic acute leukemia. Haematologica 1999;84:699-706.
7. Hanson CA, Abaza M, Sheldon S, Ross CW, Schnitzer B, Stoolman LM. Acute biphenotypic leukemia: Immuno-phenotype and cytogenetic analysis. Br J Haematol 1993;84:49-60.
8. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classifcation of acute myeloid leukemia: A report of the French -American. Ann Intern Med 1985;103:620-50.
9. Dacie and Lewis. Practical hematology. In: Lewis SM, Bain BJ, Bates I, editors. Churchill Livingstone; 9th ed. 2002. p. 269-96.
10. Harrison CJ, Radford-Weiss I, Ross F, Rack K, le Guyader G, Ve-kemans M, et al. Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations. Cancer Genet Cytogenet 1999;112:15-20.
11. Zhao L, Chang KS, Estey EH, Hayes K, Deisseroth AB, Leang JC. Detection of residual leukemic cells in patients with acute promy-elocytic leukemia by the fuorescence in situ hybridization method: Potential for predicting relapse. Blood 1995;85:495-9..
12. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, et al. Highly sensitive fuorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357-65.
13. Pais A, Amare Kadam P, Raje G, Sawant M, Kabre S, Jain H, et al. Identifcation of various MLL gene aberrations that lead to MLL gene mutation in patients with acute lymphoblastic leukemia (ALL) and infants with acute leukemia. Leuk Res 2005;29:517-26.
14. Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996;88:3704-9.
15. Shurtleff SA, Meyers S, Hiebert SW, Raimondi SC, Head DR, Willman CL, et al. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 1995;85:3695-703.
16. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic associated with translocation (11;17). Blood 1995;85:1083-94.
17. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia -specifc mRNA sequences amplifed in vitro. Proc Natl Acad Sci U S A 1988;85:5698-702.
18. Vaidya SJ, Advani SH, Pai SK, Nair CN, Kurkure PA, Saikia TK, et al. Survival of childhood acute lymphoblastic leukemia: Results of therapy at Tata Memorial Hospital, Bombay, India. Leuk Lymph 1996;20:311-5.
19. Raje N, Pai S, Vaidya S, Gopal R, Parikh P, Saikia T, et al. Adult acute lymphoblastic leukemia: results of aggressive regimen in India. Leuk Lymphoma 1994;14:285-90.
20. Sagar TG, Ramanan SG, Gupta P, Devarajan S, Ravichandran K, Rajalekshmy KR. Salvage of on therapy relapse of pediatric acute lymphoblastic leukemia: Cancer institute, Madras experience. Indian J Med Pediatr Oncol 1997;18:39-45.
21. Schrappe M. Evolution of BFM trials for childhood acute lymphob-lastic leukemia. Ann Hematol 2004;83:S121-3.
22. Schrappe M, Beier R, Burger B. New treatment strategies in childhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol 2003;15:729-40.
23. Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 2002;6:114-41.
24. Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, et al. Outcome of acute myeloid leukaemia in adults: A retrospective analysis. Natl Med J India 2005;18:12-5.
25. Jehn U. Long-term outcome of post remission chemotherapy for adults with acute myeloid leukemia using different dose-intensities. Leuk Lymph 1994;15:99-112.
26. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Capdev-ille JF, et al. Activity of a specifc inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
27. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. A phase two study of imatinib in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2002;100:1965-71.
28. Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gokbuget N, Atta J, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib mesylate (Glivac). Blood 2004;103:1495-8.
29. Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, et al. Adult biphenotypic acute leukemia: An entity with poor prognosis, which is related to unfavorable cytogenetics and P- glycophorin expression. Br J Haematol 1998;100:147-55.
30. Shen Y, Li J, Xue T, Zhu M, Lu D, Geng M, et al. Acute biphenotypic leukemia in the adults (Article in Chinese). Zhonghua Zhong Liu Za Zhi 2002;24:375-7.
31. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003;21:4377-85.
32. Nosaka T, Ohno H, Doi S, Fukuhara S, Miwa H, Kita K, et al. Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. J Clin Invest 1988;81:1824-8.
33. Briasoulis E, Tzouvara E, Tsiara S, Vartholomatos G, Tsekeris P, Baourantas K. Biphenotypic acute leukemia following intensive adjuvant chemotherapy for breast cancer: Cases report and review of literature. Breast J 2003;9:241-5.
34. Ogawa M, Porter ON, Nakahata T. Renewal and commitment to differentiation of hematopoietic stem cells. Blood 1983;61:823-9.
35. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 1986;45:917-27.
36. Felice MS, Rossi J, Gallego M, Zubirarreta PA, Cygler AM, Alfaro E, et al. Acute Trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia. Leuk Lymph 1999;34: 409-13.
37. Scolnik MP, Palacios MF, Ramirez FR, Tur R, Castuma MV, Bracco MM. Trilineage phenotypic compromise in acute leukemia. Leuk Lymph 1999;34:395-9.
38. Pui CH, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro JJ, et al. Characterisation of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78:1327-37.
39. Carbonell F, Swansburry J, Min T, Matutes E, Farahat VN, Buccheri V, et al. Cytogenetic fndings in acute biphenotypic leukemia. Leukemia 1996;10:1283-7.
40. Sulak LE, Clare CN, Morale BA, Hansen KL, Montiel MM. Biphenot-ypic acute leukemia in adults. Am J Clin Pathol 1990;94:54-8.
41. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles F, Garcia G, et al. Update of the hyper CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 2004;104:2738.
42. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high quality complete remission in majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukemia. Blood 2004;104:3507-12.
43. Ribera JM, Oriol A, Gonzalez M, Vidriales MB, Xicoy B, Grau J, et al. Treatment of Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia with concurrent chemotherapy and imatinib mesylate. Blood 2002;102:4483.
44. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an international consensus meeting. Cytometry 2001;46:23-7.
45. Gujral S, Subramanian PG, Patkar N, Badrinath Y, Kumar A, Tembhare P, et al. Report of proceedings of the national meeting on "Guidelines for Immunophenotyping of Hematolymphoid Neoplasms by Flow Cytometry". Indian J Pathol Microbiol 2008;51:161-6. 46. Lee MY, Tan TD, Feng AC. Clinicopathologic analysis of acute myeloid leukemia in a single institution: Biphenotypic acute myeloid leukemia may not be an aggressive subtype. J Chin Med Assoc 2007;70:269-73.